<DOC>
	<DOCNO>NCT01316263</DOCNO>
	<brief_summary>The purpose study evaluate tumor response stable disease ( SD ) , partial response ( PR ) , complete response ( CR ) [ accord Response Evaluation Criteria In Solid Tumors version 1.1 ( RECIST v1.1 criterion ) ] 12 week participant Gastrointestinal Stromal Tumors ( GIST ) harbor platelet-derived growth factor receptor alpha ( PDGFRα ) mutation patient GIST harbor PDGFRα mutation .</brief_summary>
	<brief_title>A Study Olaratumab ( IMC-3G3 ) Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Participant histologically cytologically confirm , unresectable and/or metastatic GIST Participant measurable disease Participant document objective progression follow , intolerance , treatment imatinib sunitinib Participant 's Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 Participant either : 1. prior result growth factor receptor associate tyrosine kinase activity ( KIT ) PDGFRα mutation analysis meet analytical criterion define onstudy analysis mutation tumor tissue ( either primary metastatic tumor ) submit analysis within 30 day first dose study therapy ; 2. prior result KIT PDGFRα mutation analysis available meet analytical criterion , tumor tissue ( either primary metastatic tumor ) must submit genotype test late 28 day prior first dose study therapy Participant adequate hematologic , hepatic , renal coagulation function Women childbearing potential sexually active male must agree use adequate contraception prior study least 12 week last dose IMC3G3 Participant life expectancy ≥ 3 month Participant untreated central nervous system metastasis , result , clinically unstable regard neurologic function Participant history another primary cancer Participant receive investigational therapy within 14 day prior registration , currently enrol type medical research Participant receive concurrent treatment anticancer therapy Participant know human immunodeficiency virus ( HIV ) infection Participant undergone major surgery within 28 day prior registration If female , participant pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>